2. 您的位置
3. 首页
4. 会议论文
5. A Mechanistic Pharmacokinetic-Pharmacodynamic Model for the Effect of Esomeprazole in Healthy Subjec

A Mechanistic Pharmacokinetic-Pharmacodynamic Model for the Effect of Esomeprazole in Healthy Subjec

来源 :第四届定量药理学与新药评价国际会议·2013(The 4th International Symposium in Qu | 被引量 : 0次 | 上传用户：eduaskbj

【摘 要】

：

Esomeprazole has proved to be effective for the treatment of gastroesophogeal reflux disease (GERD) and ulcers, where intra-gastric pH value is a biomarker to indicate esomeprazole effects on these di

【作 者】

：

Dongyang Liu Hong Yang Jiaming Qian Ji Jiang Pei Hu 

【机 构】

：

Phase Ⅰ Unit, Clinical Pharmacology Research Center, Peking Union Medical College Hospital, Peking U

【出 处】

：

第四届定量药理学与新药评价国际会议·2013(The 4th International Symposium in Qu

【发表日期】

：

2013年4期

下载到本地 , 更方便阅读

下载此文 赞助VIP

声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架

论文部分内容阅读

　　Esomeprazole has proved to be effective for the treatment of gastroesophogeal reflux disease (GERD) and ulcers, where intra-gastric pH value is a biomarker to indicate esomeprazole effects on these diseases.In our Unit, a five-way crossover study has been conducted for esomeprazole in 20 healthy volunteers.

其他文献

Polymorphisms in dihydropyrimidine dehydrogenase influence the chemotherapeutic toxicity of 5-Fu

Objective To explore the relationship between single nucleotide polymorphisms (SNP) of dihydropyrimidine dehydrogenase (DPD) and chemotherapeutic toxicity of 5-Fluorouracil (5-Fu) in patients with gas

会议

5-Fluorouracildihydropyrimidine dehydrogenasesingle nucleotide polymorphismsc

The effect of CYP3A polymorphisms on cyclosporine individual dosage regimen and blood concentration

OBJECTIVE The present study was aimed to evaluate whether the interindividual variation of cyclosporine dosages and blood concentration were associated with CYP3A4 and CYP3A5 polymorphism in renal tra

会议

cyclosporinegenetic polymorphismCYP3A4CYP3A5

Personalized Medicine Based on the Population Pharmacokinetics of Valproic Acid in Children with Epi

OBJECTIVE:To realize personalized medicine on the basis of population pharmacokinetics (PopPK) of valproic acid (VPA) in children with epilepsy.METHODS:The clinical data and VPA plasma concentrations

会议

Identification of Factors Influencing the Pharmacokinetics of Voriconazole and the Optimization of D

Objective: The objective of this study is to estimate the population pharmacokinetics of voriconazole, to identify the factors influencing voriconazole pharmacokinetics, and to identify optimal dosage

会议

Development and validation a PBPK model to predict age-dependent PK for Chinese subjects-a case stud

Aim:Todevelop and validate a general physiologicallybased pharmacokinetic (PBPK) model for hepatic pathway in Chinese adults at various ages, and to evaluate it with midazolam (substrate of CYP3A4) as

会议

Population pharmacokinetic analysis of icotinib in Chinese healthy subjects

Objective:Icotinib is a potent small-molecule inhibitor of epidermal growth factor receptor (EGFR)-tyrosine kinase (TKI), which was designed for the treatment of non-small cell lung cancer (NSCLC).It

会议

Prediction of Drug Disposition in Diabetic Patients by Means of Physiologically Based Pharmacokineti

Accumulating evidences have showed that pharmacokinetics of some drugs was altered by diabetes mellitus, leading to changes of pharmacodynamic/toxic effects.Pro-dosage prediction ofpharmacokinetics wa

会议

A semi-mechanistic population pharmacokinetic model describing the time-dependent kinetics of Red Bl

Background: XQ (Carfree, Nanjing, China), a new chemical entity that possesses pharmacological activity on PlateletActivating Factor (PAF).XQ was approved into phase Ⅰ evaluation for treatment of isch

会议

Pharmacokinetics and pharmacodynamics of a new recombinant FⅧ in haemophilia A mice

Aims:To evaluate the pharmacokinetics and pharmacodynamics properties of a new recombinant factor Ⅷ (rFⅧ), which was produced and formulated without human or animal-derived protein, and compare it wit

会议

Integrated Population Pharmacokinetic/Viral Dynamic Modeling of Lopinavir/Ritonavir in HIV-1 Treatme

Background: Lopinavir (LPV)/ritonavir (RTV) co-formulation (LPV/r) is a widely used protease inhibitor (PI) based regimen to treat HIV-infection.As with all PIs, the trough concentration (C 12h) is a

会议